A recurrent giant cell tumor of bone treated with denosumab

  • Nicola Stadler Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Thomas Fingernagel Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Stefan G. Hofstaetter Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Klemens Trieb | klemens.trieb@klinikum-wegr.at Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.

Abstract

Although the giant cell tumor of bone is generally classified as a benign tumor it can rarely metastasize and has a potential risk of local recurrence. We want to report about a female patient who suffered from a recurrence of a giant cell tumor of bone after the implantation of a total endoprosthesis of the knee joint. We have treated her with denosumab, which is a receptor activator of nuclear factor kappa-B ligand inhibitor. In this case report we want to present a new option to treat this kind of neoplasm.

Google Scholar

Google Scholar

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2015-02-10
Info
Issue
Section
Case Reports
Keywords:
bone, denosumab, tumor.
Statistics
  • Abstract views: 1186

  • PDF: 538
  • HTML: 476
How to Cite
Stadler, N., Fingernagel, T., Hofstaetter, S. G., & Trieb, K. (2015). A recurrent giant cell tumor of bone treated with denosumab. Clinics and Practice, 5(1). https://doi.org/10.4081/cp.2015.697